Christian Ruff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4651564/publications.pdf

Version: 2024-02-01

89 papers	17,945 citations	109137 35 h-index	49773 87 g-index
90 all docs	90 docs citations	90 times ranked	16598 citing authors

#	Article	IF	Citations
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	13.9	4,215
2	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	13.9	4,159
3	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, The, 2014, 383, 955-962.	6.3	3,942
4	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
5	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillationâ€“Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFâ€“TIMI 48). American Heart Journal, 2010, 160, 635-641.e2.	1.2	439
6	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
7	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2288-2295.	6.3	335
8	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation, 2016, 134, 24-36.	1.6	234
9	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	1.6	224
10	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	13.9	205
11	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. European Heart Journal, 2014, 35, 1457-1465.	1.0	174
12	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2280-2287.	6.3	153
13	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	3.8	144
14	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. Circulation, 2020, 141, 616-623.	1.6	143
15	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	139
16	Edoxaban Versus Warfarin in AtrialÂFibrillation Patients at Risk of Falling. Journal of the American College of Cardiology, 2016, 68, 1169-1178.	1.2	133
17	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation, 2017, 135, 1273-1275.	1.6	133
18	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118

#	Article	IF	Citations
19	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGEÂAF-TIMI 48 Trial. Journal of the American College of Cardiology, 2017, 69, 1372-1382.	1.2	111
20	Association of Apolipoprotein Bâ€“Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology, 2022, 7, 250.	3.0	108
21	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation, 2019, 139, 760-771.	1.6	99
22	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AFâ€TIMI48 Trial. Journal of the American Heart Association, 2016, 5, .	1.6	93
23	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1541-1550.	1.0	88
24	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	1.0	83
25	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	6.3	70
26	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1518-1527.	1.0	67
27	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. International Journal of Cardiology, 2014, 170, 413-418.	0.8	64
28	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 2020, 141, 1600-1607.	1.6	61
29	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. American Journal of Medicine, 2016, 129, 850-857.e2.	0.6	58
30	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	1.6	53
31	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationâ€. European Heart Journal, 2015, 36, 1470-1477.	1.0	47
32	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	1.0	46
33	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. European Journal of Heart Failure, 2019, 21, 1571-1579.	2.9	44
34	Transition of Patients From Blinded StudyÂDrug to Open-Label Anticoagulation. Journal of the American College of Cardiology, 2014, 64, 576-584.	1.2	39
35	Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective. Heart Rhythm, 2020, 17, 1804-1832.	0.3	38
36	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. European Heart Journal, 2017, 38, ehw565.	1.0	37

#	Article	IF	Citations
37	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation, 2018, 138, 1963-1973.	1.6	32
38	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 2019, 139, 366-375.	1.6	32
39	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
40	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	1.6	30
41	The Prognostic Significance of Cardiac Structure andÂFunction in Atrial Fibrillation: The ENGAGE AFâ€“TIMI 48 Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2016, 29, 537-544.	1.2	29
42	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 77, 1197-1207.	1.2	29
43	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. JAMA Cardiology, 2017, 2, 324.	3.0	28
44	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2021, 42, 1698-1706.	1.0	27
45	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AFâ€“TIMI 48 trial. American Heart Journal, 2015, 170, 1140-1150.	1.2	26
46	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2020, 304, 185-191.	0.8	25
47	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	0.6	24
48	Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nature Medicine, 2022, 28, 89-95.	15.2	24
49	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation, 2019, 140, 1792-1801.	1.6	22
50	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	1.8	22
51	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	1.6	21
52	First experience with edoxaban and atrial fibrillation ablation â€“ Insights from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2017, 244, 192-195.	0.8	19
53	Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. Journal of Thrombosis and Thrombolysis, 2013, 36, 361-367.	1.0	18
54	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2018, 257, 102-107.	0.8	18

#	Article	IF	Citations
55	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2018, 118, 1001-1008.	1.8	18
56	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. American Journal of Medicine, 2020, 133, 1-27.	0.6	18
57	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension, 2019, 74, 597-605.	1.3	16
58	Biomarkers for Risk Assessment in Atrial Fibrillation. Clinical Chemistry, 2021, 67, 87-95.	1.5	16
59	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillationâ€“Thrombolysis in Myocardial Infarction 48 (ENGAGE AFâ€“TIMI 48) trial. American Heart Journal, 2016, 172, 144-151.	1.2	13
60	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58Â634 patients across four randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f40-f49.	1.4	13
61	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal, 2021, 233, 48-58.	1.2	11
62	Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. PLoS ONE, 2021, 16, e0248134.	1.1	11
63	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	1.4	11
64	Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. International Journal of Cardiology, 2012, 155, 424-429.	0.8	10
65	Edoxaban Versus Warfarin in LatinÂAmerican Patients With AtrialÂFibrillation. Journal of the American College of Cardiology, 2018, 72, 1466-1475.	1.2	10
66	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation, 2021, 143, 673-684.	1.6	10
67	TIMI Risk Index and the Benefit of Enoxaparin in Patients with ST-Elevation Myocardial Infarction. American Journal of Medicine, 2007, 120, 993-998.	0.6	9
68	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hematology/Oncology Clinics of North America, 2016, 30, 1019-1034.	0.9	9
69	Personalized Anticoagulation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	8
70	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	1.2	8
71	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace, 2019, 21, 306-312.	0.7	6
72	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AFâ€“TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006511.	0.9	6

#	Article	IF	Citations
73	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	1.6	6
74	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3005-3014.	1.1	6
75	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal, 2022, 247, 24-32.	1.2	6
76	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Journal of Clinical Neuroscience, 2021, 86, 294-300.	0.8	5
77	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 695-706.	1.4	5
78	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS ONE, 2022, 17, e0266615.	1.1	5
79	Stroke Prevention in Atrial Fibrillation. Circulation, 2012, 125, e588-90.	1.6	4
80	Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. American Heart Journal, 2022, 245, 29-40.	1.2	4
81	Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine, 2022, 28, 450-451.	15.2	4
82	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. American Heart Journal, 2021, 235, 132-139.	1.2	3
83	The Promise of Mobile Health in ManagingÂAtrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 1535-1537.	1.2	2
84	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. International Journal of Cardiology, 2020, 317, 159-166.	0.8	2
85	Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. Future Cardiology, 2006, 2, 85-91.	0.5	1
86	Response. Chest, 2019, 155, 1309.	0.4	1
87	Response by Marston et al to Letter Regarding Article, â€œThe Effect of PCSK9 (Proprotein Convertase) Tj ETQq1 1 0.784314 rgBT /Ov e264.	1.6	1
88	Response. Chest, 2019, 155, 1307.	0.4	0
89	Association of APOE genotype and lipid lowering with cognitive function in a randomized placeboâ€controlled trial of Evolocumab. Alzheimer's and Dementia, 2020, 16, e047188.	0.4	0